July 7, 2021. As organizations working to promote and protect science for the public good, we are writing to express our concern about the lack of scientific evidence to support the FDA’s recent accelerated approval of Biogen’s Aduhelm (aducanumab) as a drug intended to slow cognitive damage caused by Alzheimer’s disease.
Read More »Tag: Alzheimer’s
New Alzheimer’s drug could be ‘devastating’ for Medicare
Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »NCHR Statement at FDA Alzheimer’s Advisory Committee Meeting On Aducanumab
November 6, 2020: Aducanumab could be promising, but we need better evidence before approving it.
Read More »Why isn’t there a cure for Alzheimer’s Disease or Dementia?
We reviewed a proposed 2015 controversial health law that would have had a terrible impact on the lives of Alzheimer’s patients and their families, who would have spent billions on medications that don’t work and can cause cancer.
Read More »Do Anti-Anxiety Medications Cause Dementia?
Exercise was shown to protect against the brain shrinking even if people with a family history of Alzheimer’s disease.
Read More »